219 related articles for article (PubMed ID: 25756398)
21. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
22. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
Strosberg JR; Weber JM; Choi J; Campos TL; Valone TL; Han G; Schell MJ; Kvols LK
Ann Oncol; 2012 Sep; 23(9):2335-2341. PubMed ID: 22317769
[TBL] [Abstract][Full Text] [Related]
23. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Raymond E; Faivre S; Hammel P; Ruszniewski P
Target Oncol; 2009 Dec; 4(4):253-4. PubMed ID: 19911111
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
[TBL] [Abstract][Full Text] [Related]
27. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
28. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
[TBL] [Abstract][Full Text] [Related]
29. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
[TBL] [Abstract][Full Text] [Related]
31. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract][Full Text] [Related]
32. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Faivre S; Ronot M; Dreyer C; Serrate C; Hentic O; Bouattour M; Bruno O; Couvelard A; Vilgrain V; Raymond E
Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430
[TBL] [Abstract][Full Text] [Related]
33. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Bisht S; Feldmann G; Brossart P
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Sahani DV; Jiang T; Hayano K; Duda DG; Catalano OA; Ancukiewicz M; Jain RK; Zhu AX
J Hematol Oncol; 2013 Jul; 6():51. PubMed ID: 23842041
[TBL] [Abstract][Full Text] [Related]
36. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Zhu AX; Duda DG; Ancukiewicz M; di Tomaso E; Clark JW; Miksad R; Fuchs CS; Ryan DP; Jain RK
Clin Cancer Res; 2011 Feb; 17(4):918-27. PubMed ID: 20843836
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J; González-Larriba JL; Prior C; Maroto P; Carles J; Castellano D; Mellado B; Gallardo E; Perez-Gracia JL; Aguilar G; Villanueva X; Albanell J; Calvo A
Ann Oncol; 2011 Dec; 22(12):2646-2653. PubMed ID: 21427062
[TBL] [Abstract][Full Text] [Related]
38. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
39. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
40. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
